Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-11
2008-03-11
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C424S093100, C424S093200, C424S093210
Reexamination Certificate
active
10343448
ABSTRACT:
This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo.
REFERENCES:
patent: 5834309 (1998-11-01), Thompson et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6734173 (2004-05-01), Wu et al.
patent: 2002/0091246 (2002-07-01), Pardoll et al.
patent: 2004/0028693 (2004-02-01), Wu et al.
patent: 2004/0086845 (2004-05-01), Wu et al.
patent: 2005/0277605 (2005-12-01), Wu et al.
patent: 2007/0026076 (2007-02-01), Wu et al.
patent: WO 99 07860 (1999-02-01), None
patent: WO 99 65940 (1999-12-01), None
patent: WO-01/29233 (2001-04-01), None
patent: WO-02/09645 (2002-02-01), None
patent: WO-02/12281 (2002-02-01), None
patent: WO-02/061113 (2002-08-01), None
patent: WO-03/085085 (2003-10-01), None
patent: WO-2004/098526 (2004-11-01), None
patent: WO-2005/047501 (2005-05-01), None
patent: WO-2005/081716 (2005-09-01), None
patent: WO-2006/073970 (2006-07-01), None
patent: WO-2006/081323 (2006-08-01), None
Liu et al, J Virol Mar. 2000;74:2888-94.
Peng et al, Gene Ther 2006;13:67-77.
Kerbel, Carcinogen 2000;21:505-15.
Nawrocki et al, Cancer Treat Rev 1999;25:29-46.
Nicchitta et al, Essays Biochem. 2000;36:15-25.
Harris et al, J Immunol 1998;160:5404-9.
Bennett et al, J Biol Chem 1998;273:23674-80.
Eggleton et al (Scand J Immunol 1999;49:466-73.
McCluskie et al, Mol Med May 1999;5:287-300.
Torres et al, J Immunol 1997;158:4529-32.
Nakano et al, J Virol 1997;71:7101-09.
C-H Chen et al., “Enhancement of DNA Vaccine Potency By Linkage Of Antigen Gene To ANHSP70 Gene”, Cancer Research, American Association For Cancer Research, vol. 60, pp. 1035-1042, (2000).
Sreyashi Basu et al., “Calreticulin, A Peptide-Binding Chaperone Of The Endoplasmic Reticulum, Elicits Tumor- And Peptide-Specific Immunity”, Journal of Experimental Medicine, vol. 189(5):797-802, (1999).
Wolfgang Leitner et al., “DNA And RNA-Based Vaccines: Principles, Progress And Prospects”, Vaccine, vol. 18(9-10):765-777, (1999).
Detlef Ockert et al., “Advances In Cancer Immunotherapy Symposium, Dresden, Germany”, Immunology Today, vol. 20(2):63-65, (1999).
S. Nair et al., “Calreticulin Displays In Vivo Peptide-Binding Activity And Can Elicit CTL Responses Against Bound Peptides”, Journal Of Immunology, vol. 162(11):6426-6432, (1999).
Cavill et al., “Generation of a Monoclonal Antibody Against Human Calreticulin by Immunization with a Recombinant Calreticulin Fusion Protein: Application in Paraffin-Embedded Sections,” Appl. Immunohistochemistry & Molecular Morphology 7(2):150-155 (1999).
Chang, C-L. et al., “Control of human mesothelin-expressing tumors by DNA vaccines.” Gene Therapy 1-10 (2007).
Chen, C-H. et al. “Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.” Gene Therapy 8:128-138 (2001).
Chen, C-H. et al., “Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.” Gene Therapy 6:1972-1981 (1999).
Chen, C-H. et al., “Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines,” Vaccine 18:2015-2022 (2000).
Chen, C-H. et al., “Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver.” Journal of Hepatology 33:91-98 (2000).
Chen et al., “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to ANHSP70 Gene,” Cancer Research, American Association for Cancer Research, 60:1035-1042 (2000).
Cheng, W-F. et al., “Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22-Antigen Fusion.” Human Gene Therapy. 13:553-568 (2002).
Cheng, W-F. et al. “Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen.” Journal Of Virology, 75(5): 2368-2376 (2001).
Cheng, W-F. et al. “Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Mycobacterium tuberculosis Heat Shock Protein 70 Gene to an Antigen Gene.” Journal of Immunology, 166:6218-6226 (2001).
Cheng, W-F. et al., “Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.” J. Clin. Invest. 108:669-678 (2001).
Cheng, W-F. et al. “Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Targeting Antigen to Endosomal/Lysosomal Compartments.” Human Gene Therapy 12:235-252 (2001).
Chavin, K. et al., “Obesity Induces Expression of Uncoupling Protein-2 in Hepatocytes and Promotes Liver ATP Depletion.” J. Biol. Chem. 274(9):5692-5700 (1999).
Cheng, W-F. et al., “Repeated DNA Vaccinations Elicited Qualitatively Different Cytotoxic T Lymphocytes and Improved Protective Antitumor Effects.” J Biomed Sci 9:675-687 (2002).
Cheng, W. et al., “CD8+ T cells, NK cells and IFN-γ are Important for control of tumor with downregulated MHC class I expression by DNA vaccination.” Gene Therapy 10:1311-1320, (2003).
Devaraj, K. et al., “Development of HPV Vaccines for HPV-Associated Head and Neck Squamous Cell Carcinoma,” Crit. Rev. Oral Biol. Med. 14(5):345-362, (2003).
Heller, J. et al., “Tetra-O-methyl Nordihydroguaiaretic Acid Induces G2 Arrest in Mammalian Cells and Exhibits Tumoricidal Activity in Vivo,” Cancer Research 61:5499-5504, (2001).
Hsieh, C-J. et al., “Ehnancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.” Vaccine 22:3993-4001. (2004).
Huang, C-C. et al., “HPV In Situ Hybridization With Catalyzed Signal Amplification And Polymerase Chain Reaction In Establishing Cerebellar Metastasis Of A Cervical Carcinoma.” Human Pathology, 30(5):587-591. (1999).
Huang, C-H. et al. “Cancer Immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.” Gene Therapy. 12:1180-1186 (2005).
Hung, C-F. et al., “Cancer Immunotherapy Using a DNA Vaccine Encoding the Translocation Domain of a Bacterial Toxin Linked to a Tumor Antigen.” Cancer Research 61: 3698-3703 (2001).
Hung, C-F. et al., “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to a Gene Encoding the Extracellular Domain of Fms-like Tyrosine Kinase 3-Ligand.” Cancer Research 61:1080-1088, (2001).
Hung, C-F., et al., “Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen,” Journal Of Virology, 76(6):2676-2682 (2002).
Hung, C-F. et al., “Improving DNA vaccine potency via modification of preofessional antigen presenting cells.” Current Opinion in Molecular Therapeutics, 5(1):20-24 (2003).
Hung, C-F. et al., “Enhancing Major Histocompatibility Complex Class I Antigen Presentation by Targeting Antigen to Centrosomes,” Cancer Research. 63: 2393-2398, (2003).
Hung, C-F. et al., “Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.” Gene Therapy, pp. 1-9 (2007).
Hung, C-F. et al., “DNA Vaccines Encoding li-PADRE Generates Potent PADRE-specific C
Hung Chien-Fu
Wu Tzyy-Choou
Li Q. Janice
The Johns Hopkins University
LandOfFree
Molecular vaccine linking an endoplasmic chaperone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular vaccine linking an endoplasmic chaperone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular vaccine linking an endoplasmic chaperone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3939750